Mutations in p53 from different human cancers show mutagenic patterns that are presumed to provide insight into mutagenic mechanism. mC->T mutations are prominent in colon cancer, breast cancer and leukemias and are generally thought to be due to spontaneous deamination of m5C. In lung cancer there is a preponderance of G->T mutations in the non-transcribed strand of p53, which is reminiscent of mutagenesis by bulky agents, notably polycyclic aromatic hydrocarbons (PAHs) such as benzo[a]pyrene (BP). In liver cancer, which is associated with aflatoxin B1 (AFB1) exposure, there is an extraordinary hotspot (a G->T mutation at codon 249) in p53. The PI and collaborators have been involved in several significant studies, including one showing that slow DNA repair of UV damage correlated with skin cancer hotspots in p53, and hotspots for BP adduction (and slow DNA repair) correlated with lung cancer hotspots in p53. Such correlations are consistent with (but not proof of) a role for these etiological agents in carcinogenesis involving p53 mutations. In this proposal, the PI wishes to investigate these associations at a deeper level by studying the effect of adduction hotspots and differential repair directly on mutagenesis (using a variety of assays) by a number of agents. The focus will be on the mechanism of CpG mutational hotspots associated with the presence of m5C. The PI proposes three specific aims. (1) Sites for DNA adduct formation, repair and mutagenesis with BP and AFB1 will be determined in a single system (fibroblasts from the Big Blue mouse having a lacI mutational target). (2) UV-, BP- and AFB1-induced mutations in a yeast p53-containing vector system will be collected and compared to p53 mutations from human tumors. (3) The PI will investigate whether C->T hotspots at CpGs might be due to one of four endogenous mutagens, which might generate mutations preferentially at m5C residues.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA084469-04
Application #
6633601
Study Section
Chemical Pathology Study Section (CPA)
Program Officer
Okano, Paul
Project Start
2000-07-01
Project End
2004-06-30
Budget Start
2003-07-01
Budget End
2004-06-30
Support Year
4
Fiscal Year
2003
Total Cost
$275,625
Indirect Cost
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Hanley, M P; Hahn, M A; Li, A X et al. (2017) Genome-wide DNA methylation profiling reveals cancer-associated changes within early colonic neoplasia. Oncogene 36:5035-5044
Zhang, Xiaoying; Guo, Cai; Wu, Xiwei et al. (2016) Analysis of Liver Tumor-Prone Mouse Models of the Hippo Kinase Scaffold Proteins RASSF1A and SAV1. Cancer Res 76:2824-35
Jung, Marc; Pfeifer, Gerd P (2015) Aging and DNA methylation. BMC Biol 13:7
Hahn, Maria A; Li, Arthur X; Wu, Xiwei et al. (2015) Single base resolution analysis of 5-methylcytosine and 5-hydroxymethylcytosine by RRBS and TAB-RRBS. Methods Mol Biol 1238:273-87
Jung, Marc; Kadam, Swati; Xiong, Wenying et al. (2015) MIRA-seq for DNA methylation analysis of CpG islands. Epigenomics 7:695-706
Jin, Seung-Gi; Xiong, Wenying; Wu, Xiwei et al. (2015) The DNA methylation landscape of human melanoma. Genomics 106:322-30
Hahn, Maria A; Li, Arthur X; Wu, Xiwei et al. (2014) Loss of the polycomb mark from bivalent promoters leads to activation of cancer-promoting genes in colorectal tumors. Cancer Res 74:3617-3629
Kalari, S; Jung, M; Kernstine, K H et al. (2013) The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells. Oncogene 32:3559-68
Rauch, Tibor A; Wang, Zunde; Wu, Xiwei et al. (2012) DNA methylation biomarkers for lung cancer. Tumour Biol 33:287-96
Hahn, Maria A; Wu, Xiwei; Li, Arthur X et al. (2011) Relationship between gene body DNA methylation and intragenic H3K9me3 and H3K36me3 chromatin marks. PLoS One 6:e18844

Showing the most recent 10 out of 54 publications